Kamada Granted Two Key Patents DailyFinance "The inhaled AAT is currently in a late-stage clinical trial in Europe and Canada for the treatment of Alpha-1 Antitrypsin deficiency (AATD), a genetic disease that can cause serious, life threatening lung disease in adults," said David Tsur, the Chief ... |
